Novoprotein Scientific Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	772.94	711.1	647.35	863.7	929.92	189.39
Short-Term Investments	-	-	1,154	404.51	-	-
Trading Asset Securities	-	-	-	621.7	966.85	-
Cash & Short-Term Investments	772.94	711.1	1,801	1,890	1,897	189.39
Cash Growth	12.38%	-60.52%	-4.69%	-0.36%	901.50%	101.86%
Accounts Receivable	64.57	61.77	62.02	79.97	134.66	96.58
Other Receivables	7.28	3.66	10.91	3.45	10.35	2.95
Receivables	71.85	65.43	72.93	83.42	145	99.53
Inventory	70.51	63.32	76.08	84.97	77.08	37.19
Other Current Assets	920.13	1,015	5.95	11.9	16.29	6.11
Total Current Assets	1,835	1,855	1,956	2,070	2,135	332.22
Property, Plant & Equipment	191.49	216.42	170.14	133.92	134.98	137.95
Long-Term Investments	13	10	10	-	-	-
Other Intangible Assets	17.64	17.77	18.21	18.71	18.18	6.71
Long-Term Deferred Tax Assets	24.66	23.81	31.22	27.94	18.51	12.96
Long-Term Deferred Charges	48.67	6.61	10.78	9.69	5.6	4.93
Other Long-Term Assets	14.98	21.98	21.48	38.45	21.05	18.33
Total Assets	2,146	2,152	2,218	2,299	2,333	513.1
Accounts Payable	48.53	36.23	28.26	17.94	20.9	23.64
Accrued Expenses	12.49	13.37	14.82	11.82	18.03	21.21
Current Portion of Long-Term Debt	9.15	9.48	-	-	-	-
Current Portion of Leases	-	-	17.67	13.87	13.95	8.69
Current Income Taxes Payable	0.34	1.88	0.01	1.34	5.01	4.52
Current Unearned Revenue	6.15	5.85	5.02	4.19	4.81	11.61
Other Current Liabilities	2.37	2.31	1.39	0.97	1.32	2.11
Total Current Liabilities	79.03	69.12	67.17	50.12	64.02	71.78
Long-Term Leases	43.4	45.6	48.75	59.44	69.2	78.34
Long-Term Unearned Revenue	1.51	1.55	0.52	0.87	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	-	3.21
Other Long-Term Liabilities	0.91	0.55	-	-	-	-
Total Liabilities	124.85	116.83	116.44	110.43	133.22	153.33
Common Stock	70.18	70.18	70.18	70.18	70.18	52.63
Additional Paid-In Capital	1,977	1,976	1,963	1,950	1,940	208.13
Retained Earnings	-10.03	0.57	78.36	167.86	190.1	98.82
Treasury Stock	-16.78	-11.96	-10.35	-	-	-
Comprehensive Income & Other	0.39	0.27	0.15	0.18	0.18	0.19
Shareholders' Equity	2,021	2,035	2,102	2,188	2,200	359.77
Total Liabilities & Equity	2,146	2,152	2,218	2,299	2,333	513.1
Total Debt	52.55	55.08	66.42	73.31	83.15	87.04
Net Cash (Debt)	720.39	656.02	1,735	1,817	1,814	102.36
Net Cash Growth	15.13%	-62.19%	-4.50%	0.16%	1671.86%	9.09%
Net Cash Per Share	10.24	9.36	24.87	25.46	31.79	2.56
Filing Date Shares Outstanding	70.7	69.14	69.83	70.18	70.18	52.63
Total Common Shares Outstanding	70.7	69.14	69.83	70.18	70.18	52.63
Working Capital	1,756	1,786	1,889	2,020	2,071	260.44
Book Value Per Share	28.59	29.43	30.10	31.19	31.35	6.84
Tangible Book Value	2,003	2,017	2,083	2,170	2,182	353.06
Tangible Book Value Per Share	28.34	29.17	29.84	30.92	31.09	6.71
Machinery	-	-	78.93	64.44	59.66	42.2
Construction In Progress	-	-	74.95	31.26	17.73	21.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.